Yhdysvallat - englanti - NLM (National Library of Medicine)

animart - sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb) - sodium chloride 600 mg in 100 ml - for the correction of electrolyte depletion, metabolic acidosis and dehydration of cattle, calves, horses, sheep and swine. sterile - preservative free for animal use only

Yhdysvallat - englanti - NLM (National Library of Medicine)

agrilabs - sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb) - sodium chloride 600 mg in 100 ml - for the correction of electrolyte depletion, metabolic acidosis and dehydration of cattle, calves, horses, sheep and swine.

Yhdysvallat - englanti - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid - unii:33x04xa5at), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - dextrose monohydrate 5 g in 100 ml - lactated ringer’s and 5% dextrose injection, usp is indicated as a source of water, electrolytes and calories or as an alkalinizing agent. lactated ringer’s and 5% dextrose injection, usp is contraindicated in: patients with a known hypersensitivity to sodium lactate (see warnings ).

Yhdysvallat - englanti - NLM (National Library of Medicine)

general injectables & vaccines, inc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 9 mg in 1 ml - this parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

Yhdysvallat - englanti - NLM (National Library of Medicine)

dechra veterinary products - sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at, sodium cation - unii:lyr4m0nh37), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - sodium lactate 3.17 mg in 1 ml - for the treatment of dehydration and metabolic acidosis in cattle, horses, dogs and cats. may be used to correct volume depletion (hypovolaemia) resulting from gastrointestinal disease or shock. lactate-containing solutions will not be utilised effectively in animals with hepatic impairment and it is undesirable to use this product in animals with metabolic alkalosis. any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. date on which the package leaflet was last approved: 24-04-2013

Yhdysvallat - englanti - NLM (National Library of Medicine)

a & g pharmaceuticals, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb) - sodium chloride 600 mg in 1000 ml - for the correction of electrolyte depletion, metabolic acidosis and dehydration of cattle, calves, horses, sheep and swine.

Yhdysvallat - englanti - NLM (National Library of Medicine)

sypharma pty ltd - sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698, sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (lactic acid - unii:33x04xa5at, sodium cation - unii:lyr4m0nh37) - sodium chloride 600 mg in 100 ml - sykes lactated ringer’s injection is indicated as a source of water and electrolytes for all species. it is also used as an alkalinizing agent. sykes lactated ringer’s injection is contraindicated in patients with a known hypersensitivity to sodium lactate; congestive heart failure or severe impairment of renal function; clinical states in which the administration of sodium and chloride is detrimental.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tazobactam sodium, quantity: 547 mg (equivalent: tazobactam, qty 500 mg); piperacillin sodium, quantity: 4.253 g (equivalent: piperacillin, qty 4 g) - injection, powder for - excipient ingredients: - piperacillin and tazobactam is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: lower respiratory tract infections; urinary tract infections (complicated and uncomplicated); intra-abdominal infections; skin and skin structure infections; bacterial septicaemia; and gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, piperacillin and tazobactam is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of two years. while piperacillin and tazobactam is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to piperacillin and tazobactam. therapy with piperacillin and tazobactam, however, may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once results become available, appropriate therapy should be continued. in serious infections, presumptive therapy with piperacillin and tazobactam may be initiated before susceptibility test results are available. combination therapy with piperacillin and tazobactam and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 100 mg/ml - injection - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - diagnostic: intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or opthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in the diagnosis and management of macular and vascular (including diabetic) diseases.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - pantoprazole sodium, quantity: 42.3 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; disodium edetate - short-term use where oral therapy is not appropriate for: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory drugs, whether on first presentation or recurrence.